Limited options remain for patients4-8
Patients without actionable genomic alterations need additional treatment options after initial immunotherapy and platinum‑based chemotherapy.2,3
Unfortunately, only limited options remain for patients experiencing disease progression after immunotherapy and platinum‑based chemotherapy.4‑8
References
References:
- Bubendorf L, Lantuejoul S, de Langen AJ, Thunnissen E. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. Eur Respir Rev. 2017;26(144):170007. doi: 10.1183/16000617.0007‑2017.
- Santos ES. Treatment options after first‑line immunotherapy in metastatic NSCLC. Expert Rev Anticancer Ther. 2020;20(3):221‑228. doi: 10.1080/14737140.2020.1738930.
- Grabner M, Molife C, Wang L, et al. Data on integration to improve real‑world health outcomes research for non‑small cell lung cancer in the United States: descriptive and qualitative exploration. JMIR Cancer. 2021;7(2):e23161. doi: 10.2196/23161.
- Zietemann V, Duell T. Prevalence and effectiveness of first‑, second‑, and third‑line systemic therapy in a cohort of unselected patients with advanced non‑small cell lung cancer. Lung Cancer. 2011;73(1):70‑77. doi: 10.1016/j.lungcan.2010.10.017.
- Hardesty JJ, Kanarek NF. Barriers to non‑small cell lung cancer trial eligibility. Contemp Clin Trials Commun. 2018;9:45‑49. doi: 10.1016/j.conctc.2017.11.010.
- Ford DW, Koch KA, Ray DE, Selecky PA. Palliative and end‑of‑life care in lung cancer. Chest. 2013;143(5) (Suppl):e498S‑e512S. doi: 10.1378/chest.12‑2367.
- Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response and survival in more than 50,000 patients with advanced non‑small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol. 2007;2(5):402‑407. doi: 10.1097/01.JTO.0000268673.95119.c7.
- Rothschild SI, Nachbur R, Herzog N, Passweg JR, Pless M. Second‑line therapy improves overall survival in primary refractory non‑small cell lung cancer (NSCLC) patients. ESMO Open. 2021;6(1):100013. doi: 10.1016/j.esmoop.2020.100013.
- Garon E, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second‑line treatment of stage IV non‑small‑cell lung cancer after disease progression on platinum‑based therapy (REVEL): a multicentre, double‑blind, randomized phase 3 trial. The Lancet. 2014;384(9944):665‑673. doi: 10.1016/SO140‑6736(14)60845‑X.
- Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non‑small‑cell lung cancer (LUME‑Lung1): a phase 3, double‑blind, randomized controlled trial. The Lancet. 2014;15(2):143‑155. doi: 10.1016/S1470‑2045(13)70586‑2.
- Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non‑small‑cell lung cancer previously treated with platinum‑containing chemotherapy regimens. J Clin Oncol. 2000;18(12):2354‑2362. doi: 10.1200/JCO.2000.18.12.2354.
- Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non‑small‑cell lung cancer previously treated with platinum‑based chemotherapy. Clin Oncol. 2000;18(10):2095‑2103. doi: 10.1200/JCO.2000.18.10.2095.
- Palumbo MO, Kavan P, Miller WH Jr, et al. Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol. 2013;4(57):1‑9. doi: 10.3389/fphar.2013.00057.
- Byrne MM, Tannenbaum SL, Glück S, Hurley J, Antoni M. Participation in cancer clinical trials: why are patients not participating? Med Decis Making. 2014;34(1):116‑126. doi: 10.1177/0272989X13497264.
- Bergman B, Sullivan M, Sörenson S. Quality of life during chemotherapy for small cell lung cancer: II. A longitudinal study of the EORTC core quality of life questionnaire and comparison with the sickness impact profile. Acta Oncol. 1992;31(1):19‑28. doi: 10.3109/02841869209088260.
- Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non‑small cell lung cancer. J Hematol Oncol. 2020;13(58):1‑23. doi: 10.1186/s13045‑020‑00881‑7.
- Li Z, Jiang X, Zhang W. TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun. 2016;470(1):197‑204. doi: 10.1016/j.bbrc.2016.01.032.
- Blumenthal RD, Leon E, Hansen HJ, Goldenberg DM. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer. 2007;7(2):1‑15. doi: 10.1186/1471‑2407‑7‑2.
- Deng H, Shi H, Chen L, Zhou Y, Jiang J. Over‑expression of Nectin‑4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int. 2019;19(106):1‑13. doi: 10.1186/s12935‑019‑0824‑z.
- Altan M, Pelekanou V, Schalper KA, et al. B7‑H3 expression in NSCLC and its association with B7‑H4, PD‑L1 and tumor‑infiltrating lymphocytes. Clin Cancer Res. 2017;23(17):5202‑5209. doi: 10.1158/1078‑0432.CCR‑16‑3107.
- Castellanos JR, Purvis IJ, Labak CM, et al. B7‑H3 role in the immune landscape of cancer. Am J Clin Exp Immunol. 2017;6(4):66‑75.
- Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop‑2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222‑233. doi: 10.1038/onc.2012.36.
- Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Molecular Cancer. 2010;9:253. doi: 10.1186/1476‑4598‑9‑253.
- Jiang A, Gao X, Zhang D, Zhang L, Lu H. Expression and clinical significance of the Trop‑2 gene in advanced non‑small cell lung carcinoma. Oncol Lett. 2013;6(2):375‑380. doi: 10.3892/ol.2013.1368.
- Cardillo TM, Rossi DL, Zalath MB, et al. Predictive biomarkers for sacituzumab govitecan efficacy in Trop‑2‑expressing triple‑negative breast cancer. Oncotarget. 2020;11(43):3849‑3862. doi: 10.18632/oncotarget.27766.
- Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6(3‑4):84‑105. doi: 10.18632/genesandcancer.40.
- Zhang X, Han X, Zuo P, Zhang X, Xu Hl. CEACAM5 stimulates the progression of non‑small‑cell lung cancer by promoting cell proliferation and migration. J Int Med Res. 2020;48(9):1‑15. doi: 10.1177/0300060520959478.
- Takano A, Ishikawa N, Nishino R, et al. Identification of nectin‑4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009;69(16):6694‑6703. doi: 10.1158/0008‑5472.CAN‑09‑0016.
- Pawelczyk K, Piotrowska A, Ciesielska U, et al. Role of PD‑L1 expression in non‑small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20(4):1‑15. doi: 10.3390/ijms20040824.
- Chauvin JM, Zarour H. TIGIT in cancer immunotherapy. J Immunother of Cancer. 2020;8:1‑7. doi: 10.1136/jitch‑2020‑000957.
- Huang Z, Su W, Lu T, Wang Y, et al. First‑line immune‑checkpoint inhibitors in non‑small cell lung cancer: Current landscape and future progress. Front Pharmacol. 2020;11:1‑16. doi: 10.3389/fphar.2020.578091.
- Okazaki T, Honjo T. PD‑1 and PD‑1 ligands: from discovery to clinical application. Int Immunol. 2007;19(7):813‑824. doi: 10.1093/intimm/dxm057.
- Xia L, Liu Y, Wang Y. PD‑1/PD‑L1 blockade therapy in advanced non‑small‑cell lung cancer: current status and future directions. Oncologist. 2019;24(Suppl 1):S31‑S41. doi: 10.1634/theoncologist.2019‑IO‑S1‑s05.
- Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. PNAS. 2009;106(42):17858‑17863. doi: 10.1073/pnas.0903474106.
- Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD‑1/PD‑L1. Ther Adv Respir Dis. 2018;12:1‑29. doi: 10.1177/1753466618794133.
- Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(58):1‑13. doi: 10.1186/s12943‑018‑0782‑4.
- Chen CJ, Liu YP. MERTK inhibition: potential as a treatment strategy in EGFR tyrosine kinase inhibitor‑resistant non‑small cell lung cancer. Pharmaceuticals (Basel). 2021;14(130):1‑25. doi: 10.3390/ph14020130.
- Myers KV, Amend SR, Pienta KJ. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol Cancer. 2019;18(94):1‑14. doi: 10.1186/s12943‑019‑1022‑2.
- McDaniel NK, Cummings CT, Iida M, et al. MERTK mediates intrinsic and adaptive resistance to AXL‑targeting agents. Mol Cancer Ther. 2018;17(11):2297‑2308. doi: 10.1158/1535‑7163.MCT‑17‑1239.
- Du W, Huang H, Sorrelle N, Brekken RA. Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight. 2018;3(21):1‑10. doi: 10.1172/jci.insight.124184.
- Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14(12):769‑785. doi: 10.1038/nrc3847.
- Kwilas AR, Donahue RN, Tsang KY, Hodge J. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron. 2015;2(1):1‑17. doi: 10.14800/ccm.677.
- Criscitiello C, Morganti S, Curigliano G. Antibody‑drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14(1):1‑18. doi: 10.1186/s13045‑021‑01035‑z.
- Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody‑drug conjugates. MAbs. 2016;8(4):659‑671. doi: 10.1080/19420862.2016.1156829.
- Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063‑7070. doi: 10.1158/1078‑0432.CCR‑04‑0789.
- Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9(1):86‑120. doi: 10.1007/s13238‑017‑0457‑8.
- Wu L, Seung E, Xu L, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor‑directed T cells through T cell receptor co‑stimulation. Nature Cancer. 2019. doi: 10.1038/s43018‑019‑0004‑z.
- Khongorzul P, Ling CJ, Khan FU, Ihsan AW, Zhang J. Antibody‑drug conjugates: A comprehensive review. Mol Cancer Res. 2020;18(1):3‑19. doi: 10.1158/1541‑7786.MCR‑19‑0582.
- Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non‑small cell lung cancer (NSCLC) ‑ novel approaches and future outlook. Mol Cancer. 2020;19(1):1‑15. doi: 10.1186/s12943‑020‑01260‑z.
- Gettinger SN, Redman MW, Bazhenova L, et al. Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: The lung-MAP S1400I phase 3 randomized clinical trial. JAMA Oncol. 2021;7(9):1368-1377. doi: 10.1001/jamaoncol.2021.2209.
- Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001‑2020). J Hematol Oncol. 2020;13(1):143. doi: 10.1186/s13045‑020‑00977‑0.